


Status: Currently Official on 14-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-EAE5209B-F4FA-4C29-B139-8A6489908AD0\_4\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M18540\\_04\\_01](https://doi.org/10.31003/USPNF_M18540_04_01)  
 DOI Ref: ua4g1

© 2025 USPC  
 Do not distribute

# Clonazepam



$C_{15}H_{10}ClN_3O_3$  315.71

2*H*-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-

5-(*o*-Chlorophenyl)-1,3-dihydro-7-nitro-2*H*-1,4-benzodiazepin-2-one CAS RN®: 1622-61-3; UNII: 5PE9FDE8GB.

» Clonazepam contains not less than 98.0 percent and not more than 102.0 percent of  $C_{15}H_{10}ClN_3O_3$ , calculated on the dried basis.

**Packaging and storage**—Preserve in tight, light-resistant containers, at room temperature.

**USP REFERENCE STANDARDS (11)**—

[USP Clonazepam RS](#)

[USP Clonazepam Related Compound A RS](#)

3-Amino-4-(2-chlorophenyl)-6-nitrocarbostyryl.

$C_{15}H_{10}ClN_3O_3$  315.72

[USP Clonazepam Related Compound B RS](#)

2-Amino-2'-chloro-5-nitrobenzophenone.

$C_{13}H_9ClN_2O_3$  276.68

[USP Clonazepam Related Compound C RS](#)

2-Bromo-2'-(2-chlorobenzoyl)-4'-nitroacetanilide.

**Change to read:**

▲ **SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197K▲ (CN 1-May-2020)

**MELTING RANGE (741):** between 237° and 240°.

**LOSS ON DRYING (731)**—Dry it at 105° for 4 hours: it loses not more than 0.5% of its weight.

**RESIDUE ON IGNITION (281):** not more than 0.1%.

**Limit of clonazepam related compound C—**

*Adsorbent:* 0.25-mm layer of chromatographic silica gel mixture.

*Test solution*—Dissolve an accurately weighed quantity of Clonazepam in acetone to obtain a solution having a concentration of 25 mg per mL.

*Standard solution*—Dissolve an accurately weighed quantity of [USP Clonazepam Related Compound C RS](#) in acetone to obtain a solution having a known concentration of 50 µg per mL.

*Application volume:* 20 µL.

*Developing solvent system:* a mixture of acetone and *n*-heptane (3:2).

*Procedure*—Proceed as directed for *Thin-Layer Chromatography* under [Chromatography \(621\)](#). After air-drying the plate, heavily spray the plate with 2 M sulfuric acid, and dry at 105° for 15 minutes. Successively spray the plate with 0.01 M sodium nitrite, 9 mM ammonium sulfamate, and *N*-(1-naphthyl)ethylenediamine dihydrochloride TS, and dry the plate with a current of air. Compare the intensities of any secondary spots observed in the chromatogram of the *Test solution* with that of the principal spot in the chromatogram of the *Standard solution*: no secondary spot from the chromatogram of the *Test solution* is larger or more intense than the principal spot obtained from the *Standard solution* (0.2%).

**Related compounds—**

*Buffer solution, Mobile phase, Diluent, System suitability solution, Standard preparation, and Chromatographic system*—Proceed as directed in the Assay.

*Test preparation*—Use the Assay preparation.

*Procedure*—Inject a volume (about 50 µL) of the *Test preparation* into the chromatograph, record the chromatogram, and measure the responses for all of the peaks. Calculate the percentage of each impurity in the portion of Clonazepam taken by the formula:

$$100Pr_i/(r_c + \Sigma Pr_i)$$

in which *P* is the relative response factor, which is 1.84 for clonazepam related compound A, 0.94 for clonazepam related compound B, and 1 for all other impurities; *r<sub>i</sub>* is the peak response for each impurity obtained from the *Test preparation*; and *r<sub>c</sub>* is the peak response for clonazepam in the *Test preparation*: not more than 0.1% of clonazepam related compound A or of clonazepam related compound B is found, not more than 0.2% of any other impurity is found, and the sum of all other impurities is not more than 0.3%.

#### Assay—

*Buffer solution*—Transfer about 6.6 g of anhydrous dibasic ammonium phosphate to a 1-L volumetric flask, dissolve in 950 mL of water, adjust with 1 N phosphoric acid or 1 N sodium hydroxide to a pH of 8.0, dilute with water to volume, and mix.

*Mobile phase*—Prepare a filtered and degassed mixture of *Buffer solution*, methanol, and tetrahydrofuran (60:52:13). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Diluent*—Prepare a mixture of water, methanol, and tetrahydrofuran (60:52:13).

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Clonazepam RS](#) in *Diluent*, and dilute quantitatively, and stepwise if necessary, with *Diluent* to obtain a solution having a known concentration of about 0.1 mg per mL.

*System suitability solution*—Dissolve suitable quantities of [USP Clonazepam Related Compound A RS](#), [USP Clonazepam Related Compound B RS](#), and [USP Clonazepam RS](#) in *Diluent* to obtain a solution containing about 0.04 mg per mL of each Reference Standard.

*Assay preparation*—Transfer about 10 mg of Clonazepam, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with *Diluent* to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains packing L7. The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 2.2 for clonazepam related compound A, 2.5 for clonazepam related compound B, and 1.0 for clonazepam; and the resolution, *R*, between clonazepam related compound A and clonazepam related compound B is not less than 2.0. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the tailing factor is not more than 1.5, and the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 50 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C<sub>15</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>3</sub> in the portion of Clonazepam taken by the formula:

$$100C(r_u/r_s)$$

in which *C* is the concentration, in mg per mL, of [USP Clonazepam RS](#) in the *Standard preparation*; and *r<sub>u</sub>* and *r<sub>s</sub>* are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CLONAZEPAM	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(3)

**Current DocID:** GUID-EAE5209B-F4FA-4C29-B139-8A6489908AD0\_4\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M18540\\_04\\_01](https://doi.org/10.31003/USPNF_M18540_04_01)

**DOI ref:** [ua4g1](#)